Tough road ahead for Bluebird Bio despite FDA approval for sickle cell therapy

The Food and Drug Administration’s approval on Friday of two gene therapies for sickle cell disease sets up what could be an intense competition between Bluebird Bio, maker of Lyfgenia, and the partnership of Vertex Pharmaceuticals and CRISPR Therapeutics, whose drug is Casgevy. For the first…#bluebirdbio #lyfgenia #crisprtherapeutics #vertex #crispr
Source: Reuters: Health - Category: Consumer Health News Source Type: news